$9 Billion Verdict – Actos
As of early this morning, April 8, 2014, the makers of Actos, Takeda Pharmaceutical Co. and their marketing partner, Eli Lilly and Co., are facing a total of $9 billion in punitive damages – the seventh largest verdict in U.S. History for former Actos user Terrence Allen.
Takeda, Lilly Jury Awards $9 Billion in Actos Cancer Case
As of early this morning, April 8, 2014, the makers of Actos, Takeda Pharmaceutical Co. and their marketing partner, Eli Lilly and Co., are facing a total of $9 billion in punitive damages – the seventh largest verdict in U.S. History for former Actos user Terrence Allen. The Jury in Lafayette, Louisiana decided that the drug makers hid the risk of major side effects from its patients.
“This is what happens when a pharmaceutical company puts profits over safety. Both Takeda and Eli Lilly need to hear this jury loud and clear. This conduct will not be tolerated,” said Chris Seeger, founding partner of Seeger Weiss LLP.
Takeda Pharmaceuticals, Asia’s largest drug maker, has been ordered to pay $6 billion in punitive damages, while Eli Lilly and Co has been order to pay $3 billion. Takeda disagreed with the Louisiana jury verdict and that they would fight to overturn it. The verdict was announced at a changing time for Takeda as a new chief officer, Christophe Weber, came into office. Weber described reasons why he took the job; in part he took the position because of Takeda’s ethical commitments.
Actos is a drug prescribed to patients with type 2 diabetes. There have been recent studies which link the use of Actos to bladder cancer and heart failure. Actos entered the U.S market in 1999 and became a blockbuster drug for Takeda Pharmaceuticals, with global sales of over $3.85 billion. After their patent expired in 2011, the drug company’s sales decreased. Takeda struggled to develop new remedies to gain back lost revenue after Germany and France discontinued sales of the drug due to the high risk of cancer tied to the drug.
According to the current label for Actos in the U.S, a study found those who have used the drug for more than two years had a higher risk of developing bladder cancer. The study also found, those patients who used Actos long-term increased the risk of developing bladder cancer by nearly 40%.
Seeger Weiss, LLP is proud to congratulate the Actos trail team for a successful verdict against Takeda and Lilly of $9 Billion in this diabetes cancer case. Seeger Weiss, LLP is an active member of the Actos leadership and will continue to help clients affected by the drug as this litigation continues. With experienced attorneys and locations throughout the United States, our firm strives to provide the highest quality of service to our clients. We treat each case with careful attention to ensure that consumers get the justice they deserve.
If you or a loved one has been diagnosed with bladder cancer after taking one of these drugs, fill out our free case review form today to contact our actos bladder cancer lawyers to find out if you can file a claim seeking compensation for medical bills, pain and suffering and other damages.
Valeant Pharmaceuticals International is a fast-growing company that is creating life and death scenarios for patients that rely on its drugs. This summer, nearly overnight, Valeant quadrupled its [...]October 5, 2015 By: Seeger Weiss LLP read more